Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Rating of “Hold” by Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Rating) have earned a consensus recommendation of “Hold” from the ten research firms that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, six have given a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $10.19.

Several equities analysts recently weighed in on TBPH shares. StockNews.com started coverage on shares of Theravance Biopharma in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. Morgan Stanley raised their price target on shares of Theravance Biopharma from $10.00 to $11.00 and gave the company an “underweight” rating in a research report on Wednesday, March 2nd. Finally, HC Wainwright raised their price target on shares of Theravance Biopharma from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, February 24th.

Shares of TBPH opened at $9.93 on Friday. The stock has a 50-day moving average of $9.71 and a 200-day moving average of $9.25. The company has a market cap of $753.69 million, a PE ratio of -3.37 and a beta of 0.86. Theravance Biopharma has a one year low of $6.10 and a one year high of $22.74.

Theravance Biopharma (NASDAQ:TBPH – Get Rating) last issued its earnings results on Wednesday, February 23rd. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.13). The firm had revenue of $14.95 million during the quarter, compared to the consensus estimate of $15.59 million. During the same period in the previous year, the company posted ($0.92) EPS. Equities research analysts predict that Theravance Biopharma will post 0.54 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. Amalgamated Bank bought a new stake in shares of Theravance Biopharma during the 3rd quarter worth $78,000. BNP Paribas Arbitrage SA raised its stake in shares of Theravance Biopharma by 420.5% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 10,790 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 8,717 shares during the period. Rafferty Asset Management LLC bought a new stake in shares of Theravance Biopharma during the 3rd quarter worth $94,000. Jane Street Group LLC bought a new stake in shares of Theravance Biopharma during the 3rd quarter worth $107,000. Finally, Arizona State Retirement System raised its stake in shares of Theravance Biopharma by 20.8% during the 3rd quarter. Arizona State Retirement System now owns 14,705 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 2,531 shares during the period. 81.80% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma (Get Rating)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

Featured Stories